Patent SG-11201903063U-A (SG)
Title: Anti-o1 antibodies and uses thereof
Inventor: WANG QUN
IPC: A61K39/40
Filed: 2017-10-16
Abstract: FIGA LPS-01 ELISA KP.A27 -e- 59H7 - KPB202 KPE 33 K1 7 .1 mAla concentration [ngimi] W O 20 18/075 375 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT omit VIII °nolo ovilioillinnovoimIE (10) International Publication Number WO 2018/075375 Al (51) International Patent Classification: C07K 16/12 (2006.01) A61K 39/40 (2006.01) A61K 39/395 (2006.01) (21) International Application Number: PCT/US2017/056725 (22) International Filing Date: 16 October 2017 (16.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/410,005 19 October 2016 (19.10.2016) US (71) Applicants: MEDIMMUNE, LLC [US/US]; One Medlm- mune Way, Gaithersburg, Maryland 20878 (US). HUM- ABS BIOMED SA [CH/CH]; Mirasole 1, CH-6500 Bellinzona (CH). (72) Inventors: WANG, Qun; MedImmune, LLC, One Medlm- mune Way, Gaithersburg, 20878 (US). STOVER, Charles K.; Medlmmune, LLC, One MedImmune Way, Gaithers- burg, Maryland 20878 (US). PENNINI, Meghan; Medlm- mune, LLC, One MedImmune Way, Gaithersburg, Mary- land 20878 (US). CHANG, Chew-Shun; Medlmmune, LLC, One Medlmmune Way, Gaithersburg, Maryland 20878 (US). XIAO, Xiaodong; Medlmmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). HILLIARD, Jamese; Medlmmune, LLC, One MedIm- mune Way, Gaithersburg, Maryland 20878 (US). KA- PLAN, Gilad; MedImmune, LLC, One MedImmune Way, Gaithersburg, Maryland 20878 (US). CORTI, Davide; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). CAMERONI, Elisabetta; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). BELTRAMEL- LO, Martina; Humabs BioMed SA, Mirasole 1, CH-6500 Bellinzona (CH). (74) Agent: MARTIN, Cynthia Lan et al.; MedImmune, LLC, One Medlmmune Way, Gaithersburg, Maryland 20878 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: ANTI-01 ANTIBODIES AND USES THEREOF (57) : The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to Klebsiella pneumoniae 01 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiella pneumoniae). The present disclosure also provides methods of reducing Klebsiella (e.g., Klebsiella pneumoniae) or treating or pre- venting Klebsiella (e.g., Klebsiella pneumoniae) infection in a subject comprising adminis- tering the Klebsiella pneumoniae 01 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject. FIG. 1B SBA of 4211-lux 0^ 10° 10' 10' 10 0 mAb concentration [ngimi] FIG. 1C OPK of 43816dCpsB 10' 10' BM 10. 10' 10' 10. 10' mAlt concentration [ngimi] [Continued on next page] 100 ▪ 50 100 0 KPA27 ▪ 54H7 - KPB202 KPE33 A- K1,14 KPA2] -a- 54H7 KPB202 ▪ KPE33 KI 7 .14 WO 2018/075375 Al MIDEDIMOMOIDEIREIDIONOMINOMEOMEMOIMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))